San Francisco, California, May 15, 2017: Retinitis pigmentosa is a medical condition inherited, which causes retinal degeneration. Since there are no treatments available for curing retinitis pigmentosa, they are much awaited and a great potential lies for new players venturing in the market. TMR Research in its latest report, studies the global business process as a service market. The report is titled “Retinitis Pigmentosa (RP) Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025.”
According to the report, the untapped medical needs for patients suffering from retinitis pigmentosa are making it a highly competitive arena and this will drive players and researchers into extensive investments and studies. In the past, several attempts have been made to slow down the degeneration process of the retina by consuming the supplement of 15,000 I.U. of Vitamin A or by consuming fish oil. However, the actual treatment is yet to be discovered, creating opportunities of growth in the market.
The report is an extensive overview of the retinitis pigmentosa market, describing this medical condition, its causes, and attempts to control the degeneration. It discusses in detail, the factors contributing to the growth of the market and those factors that act as a challenge and hampers any further growth of the market. The impact analysis of both driving and challenging factors is included in the report. Also given, is a brief history of all the key players operating in the global retinitis pigmentosa market.
The global retinitis pigmentosa market is treading towards growth in a slow manner owing to the unavailability of therapeutics to cure this rare disease. However, this has also opened doors of opportunity for players, as they take up the challenge to fight this medical condition and come up with effective cure and treatment. People afflicted with generic disorders are not receiving proper treatment due to a lack of proper cure and this is resulting in retinitis pigmentosa. Thus, there is a high demand for therapeutics that can restore vision. The approval of Argus II retinal prosthesis system by the FDA is creating a hope for patients, as it enhances a person’s ability to see and recognize movement and images.
Another new approach by the name of optogenetics is being implemented and further researched upon, by companies from the ophthalmology market. This new approach makes use of gene therapy for restoring lost sight. Such positive developments are expected to boost the confidence of players in the market and encourage them to further their efforts in researching and developing effective treatment options. Leading players operating in the market include: ReGenX Biosciences, LLC, ReNeuron Group plc, Ocugen, Inc., Orphagen Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Okuvision GmbH, and Amarantus BioScience Holdings, Inc.